Transcranial Magnetic Stimulation (TMS) has proven its efficacy in providing relief for OCD sufferers who still have symptoms after 1st line treatment. But until recently, some patients who needed this treatment to reclaim their lives from intrusive obsessions and compulsions did not have the support of major insurance carriers.
CIGNA recently announced the decision to extend coverage to BrainsWay’s Deep TMS technology for OCD treatment. While BrainsWay’s Deep TMS treatment for OCD already had the support of some other carriers*, this decision gives Cigna’s 17 million members the access to the most effective treatment option available! Of note, this is a medication free modality, without the risk of additional side effects that are commonly associated with SSRI treatment.
Here at Hudson, our experts use BrainsWay’s state-of-the-art Deep TMS H7 coil system to serve patients with treatment-resistant OCD and Depression. BrainsWay has established itself as a leader in the development of noninvasive neurostimulation technology. Now, with more carriers supporting these treatments, the reach of organizations like BrainsWay will expand and lead to more opportunities for patients to break through debilitating OCD. We want patients to get their life back! With 58% of patients experiencing significant improvement in symptoms, and FDA Clearance, we are excited to make this even more available.
Learn more about Cigna’s decision to extend coverage for Deep TMS treatments for OCD here.
*Carriers that support BrainsWay Deep TMS for OCD:
Health Care Services Corporation
Some Blue Cross Blue Shield Plans
Palmetto GBA Medicare